Table 1 Correlation analysis between CD27 expression and clinical factors in 82 patients
From: Prognostic marker CD27 and its micro-environmental in multiple myeloma
Variable | Subcategory | CD27 + group (n = 60) | CD27-group (n = 22) | P value |
|---|---|---|---|---|
Gender | female | 27(45.00%) | 10(45.45%) | 0.971 |
male | 33(55.00%) | 12(54.55%) | ||
Age(year) | ≥ 65 | 25(41.67%) | 12(54.55%) | 0.299 |
< 65 | 35(58.33%) | 10(45.45%) | ||
HGB(g/L) | ≥ 100 | 38(63.33%) | 10(45.45%) | 0.145 |
< 100 | 22(36.67%) | 12(54.55%) | ||
Ca(mmol/L) | ≥ 2.75 | 12(20.00%) | 5(22.73%) | 0.787 |
< 2.75 | 48(80.00%) | 17(77.28%) | ||
ALB(g/L) | ≥ 35 | 31(51.67%) | 15(68.18%) | 0.182 |
< 35 | 29(48.33%) | 7(31.82%) | ||
Cr(μmol/L) | ≥ 177 | 18(30.00%) | 8(36.36%) | 0.583 |
< 177 | 42(70.00%) | 14(63.64%) | ||
LDH(U/L) | ≥ 246 | 24(40.00%) | 12(54.55%) | 0.240 |
< 246 | 36(60.00%) | 10(45.45%) | ||
β2-MG (mg/L) | ≥ 3.5 | 39(65.00%) | 8(36.36%) | 0.020 |
< 3.5 | 21(35.00%) | 14(63.64%) | ||
BMPC proportion (%) | ≥ 31.49 | 36(60.00%) | 6(27.27%) | 0.009 |
< 31.49 | 24(40.00%) | 16(72.73%) | ||
ISS stage | I -II | 40(66.67%) | 17(77.28%) | < 0.001 |
III | 20(33.33%) | 5(22.73%) |